Targeted probes such as PARPiFL (targeting poly-ADP ribose polymerase (PARP)) are also available, which work by binding selectively to targets that are overexpressed in cancer cells and are therefore more specific to tumour tissue. This evidence concerns the gene PARP1 and neoplasm.